ixekizumab治疗中重度斑块型银屑病的临床应用

IF 5.2 Q1 DERMATOLOGY
Psoriasis (Auckland, N.Z.) Pub Date : 2017-11-16 eCollection Date: 2017-01-01 DOI:10.2147/PTT.S129792
Sahil Sekhon, Caleb Jeon, Mio Nakamura, Di Yan, Ladan Afifi, Tina Bhutani, Ethan Levin
{"title":"ixekizumab治疗中重度斑块型银屑病的临床应用","authors":"Sahil Sekhon,&nbsp;Caleb Jeon,&nbsp;Mio Nakamura,&nbsp;Di Yan,&nbsp;Ladan Afifi,&nbsp;Tina Bhutani,&nbsp;Ethan Levin","doi":"10.2147/PTT.S129792","DOIUrl":null,"url":null,"abstract":"<p><p>Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"7 ","pages":"65-72"},"PeriodicalIF":5.2000,"publicationDate":"2017-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S129792","citationCount":"7","resultStr":"{\"title\":\"Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.\",\"authors\":\"Sahil Sekhon,&nbsp;Caleb Jeon,&nbsp;Mio Nakamura,&nbsp;Di Yan,&nbsp;Ladan Afifi,&nbsp;Tina Bhutani,&nbsp;Ethan Levin\",\"doi\":\"10.2147/PTT.S129792\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.</p>\",\"PeriodicalId\":74589,\"journal\":{\"name\":\"Psoriasis (Auckland, N.Z.)\",\"volume\":\"7 \",\"pages\":\"65-72\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2017-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/PTT.S129792\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psoriasis (Auckland, N.Z.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/PTT.S129792\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psoriasis (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/PTT.S129792","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 7

摘要

寻常型牛皮癣是一种慢性、免疫介导的全身性疾病,在美国有affectŝ7.5百万患者。它可以用许多疗法来治疗,通常是联合治疗,包括外敷、光疗、口服系统和生物制剂。生物制剂针对银屑病发病机制中涉及的免疫系统的特定成分,包括tnf - α, IL-12, IL-17和IL-23。生物制剂ixekizumab在美国被批准用于治疗中重度斑块性银屑病,靶向IL-17。本文综述了IL-17在银屑病中的作用,ixekizumab靶向该细胞因子的机制,以及ixekizumab的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信